TRCT
DNLI icon

Tower Research Capital (TRC)’s Denali Therapeutics DNLI Stock Holding History

Tower Research Capital (TRC)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403K Buy
20,978
+8,037
+62% +$160K 0.01% 1076
2025
Q4 		$214K Buy
12,941
+5,565
+75% +$93.9K 0.01% 1388
2025
Q3 		$107K Sell
7,376
-6,293
-46% -$90.4K ﹤0.01% 1934
2025
Q2 		$191K Buy
13,669
+10,457
+326% +$147K 0.01% 1820
2025
Q1 		$43.7K Sell
3,212
-8,076
-72% -$155K ﹤0.01% 2321
2024
Q4 		$230K Buy
11,288
+10,857
+2,519% +$278K ﹤0.01% 1622
2024
Q3 		$12.6K Sell
431
-20,401
-98% -$506K ﹤0.01% 3576
2024
Q2 		$484K Buy
20,832
+19,407
+1,362% +$373K 0.01% 1375
2024
Q1 		$29.2K Sell
1,425
-4,299
-75% -$80.8K ﹤0.01% 2672
2023
Q4 		$123K Buy
5,724
+4,016
+235% +$79.5K ﹤0.01% 2482
2023
Q3 		$35.2K Sell
1,708
-4,282
-71% -$109K ﹤0.01% 2874
2023
Q2 		$177K Buy
5,990
+1,985
+50% +$55.8K 0.01% 1643
2023
Q1 		$92K Buy
4,005
+2,451
+158% +$67.5K ﹤0.01% 1943
2022
Q4 		$44K Sell
1,554
-12,662
-89% -$377K ﹤0.01% 2447
2022
Q3 		$437K Buy
14,216
+3,700
+35% +$120K 0.01% 1252
2022
Q2 		$309K Buy
10,516
+8,419
+401% +$221K 0.01% 1457
2022
Q1 		$68K Sell
2,097
-5,242
-71% -$180K ﹤0.01% 2487
2021
Q4 		$328K Buy
7,339
+1,924
+36% +$91.2K 0.01% 1413
2021
Q3 		$273K Buy
5,415
+888
+20% +$50K 0.01% 1508
2021
Q2 		$355K Sell
4,527
-3,135
-41% -$194K 0.01% 1459
2021
Q1 		$437K Buy
7,662
+3,625
+90% +$243K 0.01% 1353
2020
Q4 		$338K Buy
4,037
+1,731
+75% +$105K 0.01% 1305
2020
Q3 		$83K Sell
2,306
-7,275
-76% -$219K ﹤0.01% 3286
2020
Q2 		$232K Buy
+9,581
New +$225K 0.01% 1667
2019
Q4 		– Sell
-2,095
Closed -$32K – 3707
2019
Q3 		$32K Buy
2,095
+1,980
+1,722% +$37.8K ﹤0.01% 2138
2019
Q2 		$2K Sell
115
-713
-86% -$16K ﹤0.01% 3249
2019
Q1 		$19K Buy
828
+721
+674% +$15.1K ﹤0.01% 2291
2018
Q4 		$2K Buy
+107
New +$1.94K ﹤0.01% 3337
2018
Q3 		– Sell
-3,668
Closed -$56K – 3859
2018
Q2 		$56K Buy
+3,668
New +$69.1K ﹤0.01% 1784

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s DNLI Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Denali Therapeutics (DNLI) stake by 62% in Q1 2026, buying an estimated $160K and bringing the position to 20,978 shares worth $403K. The position accounts for 0.01% of the portfolio, ranked #1076.

Tower Research Capital (TRC) first reported a position in DNLI in Q2 2018 and has held it in 29 quarters since. The position peaked at $484K in Q2 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Tower Research Capital (TRC) held 20,978 shares of Denali Therapeutics worth $403K as of Q1 2026.
  • Tower Research Capital (TRC) bought 8,037 Denali Therapeutics shares in Q1 2026, an estimated $160K.
  • Denali Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1076 holding.
  • Tower Research Capital (TRC) first reported a position in Denali Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Denali Therapeutics position peaked at $484K in Q2 2024.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.